Skip to main content
Premium Trial:

Request an Annual Quote

New York Genome Center Buys Illumina HiSeq X Ten

Premium

A week after Illumina announced its new high-throughput sequencing platform, the HiSeq X Ten, the New York Genome Center said it has purchased one of the systems.

Bob Darnell, NYGC's CEO, president, and scientific director, told In Sequence that the decision to acquire the HiSeq X Ten resulted from the necessity to move from exome sequencing to whole-genome sequencing in order to be able to capture disease-causing mutations that would otherwise be missed. "The future is being more comprehensive," he said.

The center expects the new instruments to arrive by the end of March, according to Darnell. Initially, they will be mostly used for work by members of the New York Genome Center, but longer term the center plans to engage in academic collaborations to make full use of the system's capacity, he said.

Each of the 10 units can generate about 1.8 terabases of data in under three days, or 15 human genomes at high coverage, so the theoretical output of the system is more than 18,000 genomes per year, at a cost of under $1,000 per genome, according to Illumina.

Illumina sells the instrument in sets of 10 for a total of $10 million, and customers are only permitted to use the HiSeq X Ten for human whole-genome sequencing.

Other than the NYGC, the first customers are the Broad Institute, the Garvan Institute in Australia, and Macrogen in Korea.

Illumina said it can ship the HiSeq X Ten to up to five customers this year, though it might be able to increase its manufacturing capacity to accommodate more customers.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more